{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:22:52Z","timestamp":1792977772616,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejphar.2021.173933","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T16:40:24Z","timestamp":1612284024000},"page":"173933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["MiRNA-138\u20135p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis"],"prefix":"10.1016","volume":"896","author":[{"given":"Mina","family":"Rasoolnezhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-6998","authenticated-orcid":false,"given":"Reza","family":"Safaralizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Hosseinpourfeizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahdi","family":"Banan-Khojasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-6795","authenticated-orcid":false,"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejphar.2021.173933_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molmed.2011.01.006","article-title":"MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer","volume":"17","author":"Andorfer","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2021.173933_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.12968\/hmed.2019.80.12.720","article-title":"Genetics of breast cancer: management strategies and risk-reducing surgery","volume":"80","author":"Balasubramanian","year":"2019","journal-title":"Br. J. Hosp. Med."},{"key":"10.1016\/j.ejphar.2021.173933_bib3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.biopha.2018.10.177","article-title":"Dysregulation of key microRNAs in pancreatic cancer development","volume":"109","author":"Baradaran","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.ejphar.2021.173933_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.rmed.2015.02.006","article-title":"MicroRNA as tools and therapeutics in lung cancer","volume":"109","author":"Barger","year":"2015","journal-title":"Respir. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2021.173933_bib5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.yexcr.2013.02.025","article-title":"miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo","volume":"319","author":"Chakrabarti","year":"2013","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.ejphar.2021.173933_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.ejphar.2021.173933_bib7","doi-asserted-by":"crossref","first-page":"21609","DOI":"10.18632\/oncotarget.15450","article-title":"The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1","volume":"8","author":"Cioffi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2021.173933_bib8","doi-asserted-by":"crossref","first-page":"144301","DOI":"10.1016\/j.gene.2019.144301","article-title":"An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer","volume":"729","author":"Dastmalchi","year":"2020","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.ejphar.2021.173933_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173933_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin. Canc. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173933_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.ejphar.2021.173933_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/648589","article-title":"Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513","volume":"201","author":"Gong","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ejphar.2021.173933_bib13","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173933_bib14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Canc. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2021.173933_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep24193","article-title":"Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1-and prostaglandin E 2-induced regulatory T cell expansion","volume":"6","author":"Holla","year":"2016","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ejphar.2021.173933_bib16","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/jcp.26514","article-title":"Treating cancer with microRNA replacement therapy: a literature review","volume":"233","author":"Hosseinahli","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173933_bib17","first-page":"RA32","article-title":"Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review","volume":"15","author":"Jezierska","year":"2009","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173933_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbrc.2017.05.074","article-title":"miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity","volume":"488","author":"Jia","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.ejphar.2021.173933_bib19","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.ejphar.2021.173933_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejphar.2021.173933_bib21","doi-asserted-by":"crossref","first-page":"8316","DOI":"10.1002\/jcp.27716","article-title":"Key microRNAs in the biology of breast cancer; emerging evidence in the last decade","volume":"234","author":"Khordadmehr","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"48","key":"10.1016\/j.ejphar.2021.173933_bib22","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1038\/onc.2015.89","article-title":"MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment","volume":"34","author":"Kohlhapp","year":"2015","journal-title":"Oncogene"},{"issue":"82","key":"10.1016\/j.ejphar.2021.173933_bib23","doi-asserted-by":"crossref","first-page":"52030","DOI":"10.1039\/C7RA09042K","article-title":"MiR-138-5p targeting LIMK1 suppresses breast cancer cell proliferation and motility","volume":"7","author":"Li","year":"2017","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173933_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2009.05.030","article-title":"MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines","volume":"286","author":"Liu","year":"2009","journal-title":"Canc. Lett."},{"issue":"7043","key":"10.1016\/j.ejphar.2021.173933_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejphar.2021.173933_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Canc. Cell"},{"issue":"4","key":"10.1016\/j.ejphar.2021.173933_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/tox.22708","article-title":"Overexpression of miR-138-5p suppresses MnCl2-induced autophagy by targeting SIRT1 in SH-SY5Y cells","volume":"34","author":"Ma","year":"2019","journal-title":"Environ. Toxicol."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173933_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-010-0734-1","article-title":"Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT)","volume":"124","author":"Martin","year":"2010","journal-title":"Breast Canc. Res. Treat."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173933_bib29","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers7020815","article-title":"Effects of age on the detection and management of breast cancer","volume":"7","author":"McGuire","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2021.173933_bib30","first-page":"1355","article-title":"Al-Thubaity f, Gari MA, Chaudhary AG, Abuzenadah AM and Al-Qahtani MH: expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis","volume":"34","author":"Merdad","year":"2014","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.ejphar.2021.173933_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Canc. Immunol. Res."},{"key":"10.1016\/j.ejphar.2021.173933_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.biopha.2016.09.099","article-title":"The role of microRNAs in colorectal cancer","volume":"84","author":"Mohammadi","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.ejphar.2021.173933_bib33","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1002\/jcp.28058","article-title":"MicroRNA replacement therapy in cancer","volume":"234","author":"Mollaei","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"22","key":"10.1016\/j.ejphar.2021.173933_bib34","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1158\/0008-5472.CAN-13-1841","article-title":"miRNA dysregulation in breast cancer","volume":"73","author":"Mulrane","year":"2013","journal-title":"Canc. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2021.173933_bib35","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Canc. Res."},{"issue":"8","key":"10.1016\/j.ejphar.2021.173933_bib36","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin. Canc. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173933_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3727\/096504017X15017209042610","article-title":"Decreased expression of miR-138-5p by lncRNA H19 in cervical cancer promotes tumor proliferation","volume":"26","author":"Ou","year":"2018","journal-title":"Oncol. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2021.173933_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317697575","article-title":"MiR-138: a promising therapeutic target for cancer","volume":"39","author":"Sha","year":"2017","journal-title":"Tumor Biol."},{"issue":"5","key":"10.1016\/j.ejphar.2021.173933_bib39","first-page":"3213","article-title":"Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer","volume":"11","author":"Si","year":"2019","journal-title":"Am. J. Tourism Res."},{"key":"10.1016\/j.ejphar.2021.173933_bib40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3389\/fcell.2020.00540","article-title":"MicroRNA-138-5p suppresses non-small cell lung cancer cells by targeting PD-L1\/PD-1 to regulate tumor microenvironment","volume":"8","author":"Song","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.ejphar.2021.173933_bib41","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173933_bib42","doi-asserted-by":"crossref","first-page":"709s","DOI":"10.1158\/1078-0432.CCR-06-1868","article-title":"Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin. Canc. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2021.173933_bib43","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Canc. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2021.173933_bib44","doi-asserted-by":"crossref","first-page":"11071","DOI":"10.18632\/oncotarget.14360","article-title":"miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ejphar.2021.173933_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase\/AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Canc."},{"issue":"12","key":"10.1016\/j.ejphar.2021.173933_bib46","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/ijms18122540","article-title":"The roles of microRNAs in regulating the expression of PD-1\/PD-L1 immune checkpoint","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173933_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell. Signal."},{"issue":"17","key":"10.1016\/j.ejphar.2021.173933_bib48","doi-asserted-by":"crossref","first-page":"28125","DOI":"10.18632\/oncotarget.15924","article-title":"MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejphar.2021.173933_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem."},{"issue":"6","key":"10.1016\/j.ejphar.2021.173933_bib50","first-page":"5272","article-title":"Downregulation of miR-138-5p promotes non-small cell lung cancer progression by regulating CDK8","volume":"20","author":"Xing","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2021.173933_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/onc.2012.557","article-title":"BCR-ABL\/GATA1\/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia","volume":"33","author":"Xu","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ejphar.2021.173933_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms11406","article-title":"miR-424 (322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint","volume":"7","author":"Xu","year":"2016","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ejphar.2021.173933_bib53","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/stem.1149","article-title":"MiR-138 promotes induced pluripotent stem cell generation through the regulation of the p53 signaling","volume":"30","author":"Ye","year":"2012","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejphar.2021.173933_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biopha.2015.12.018","article-title":"MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin","volume":"77","author":"Zhang","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.ejphar.2021.173933_bib55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cbin.10826","article-title":"Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1","volume":"41","author":"Zhang","year":"2017","journal-title":"Cell Biol. Int."},{"issue":"6","key":"10.1016\/j.ejphar.2021.173933_bib56","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12282-019-00989-w","article-title":"MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1","volume":"26","author":"Zhao","year":"2019","journal-title":"Breast Cancer"},{"issue":"29","key":"10.1016\/j.ejphar.2021.173933_bib57","doi-asserted-by":"crossref","first-page":"45370","DOI":"10.18632\/oncotarget.9659","article-title":"The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejphar.2021.173933_bib58","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.3892\/ol.2016.5038","article-title":"MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer","volume":"12","author":"Zhou","year":"2016","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173933_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150026","article-title":"MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells","volume":"11","author":"Zhu","year":"2016","journal-title":"PloS One"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:48:34Z","timestamp":1757976514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":59,"alternative-id":["S0014299921000868"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173933","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiRNA-138\u20135p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173933"}}